
Electrophysiology: Life Changing Programs
My Electrophysiology Story I remember the first time I saw a permanent pacemaker being placed in a cardiac cath lab by a cardiologist. At that time, it was fairly interesting…
Atrial fibrillation (AF) is the most common heart arrhythmia, and according to the CDC, its prevalence has only been increasing, a trend that will continue. In fact, estimates reveal that 12.1 million people in the United States will have AF by 2030 (CDC, 2021). However, it is encouraging that steady progress and advances in novel anticoagulants, along with the refinement of tools in invasive therapy for AF in the form of catheter ablation, have substantially improved outcomes for patients with this disease. Further, encouraging results from The CASTLE trial proved that AF ablation is a valuable clinical treatment to preserve normal sinus rhythm (Marrouche et al, 2018).
In 2019, AHA/ACC/HRS provided a focused update of the 2014 AHA/ACC/HRS Guidelines for the Management of Patients With Atrial Fibrillation. Reflective of the latest research, the update provided for a class IIb recommendation for catheter ablation, thus allowing for more aggressive use of both ablation and device therapies (January, Wann, 2019).
Electrophysiology is one of the fastest-growing sub-specialty service lines within cardiology in part due to the pace at which new technologies are introduced. But this fact, along with varied equipment and device needs, make EP one of the most expensive as well. Hospitals considering expansion of EP services should consider the effort in the context of the increasing role of AF ablation in the management of this condition, and some of the remarkable new tools that aim to increase efficacy and safety of catheter AF ablation:
While some of the continuing improvements in the diagnosis and treatment of AF will be driven by the advancement of existing tools and products, innovative technologies are on the horizon as well. Such developments will enhance the abilities of catheter mapping and ablation of cardiac arrhythmias, which can only further enrich patient and procedural outcomes. And while the future promises pioneering changes to the field of cardiac electrophysiology, device and ablation technology continues to discover new treatment approaches and push the boundaries of past limitations for these chronic patients.
If you need help identifying whether expansion of EP services is right for your hospital, Corazon can help! Start by determining the scope and type of program, which is just as important as gauging the potential for profitability when making the decision to expand EP offerings. Corazon can help identify which services are right based on your market potential, existing program scope, and cardiovascular opportunity overall.
References: